 Phase I-II trial pentoxifylline prevention transplant-related toxicities bone marrow transplantation Disease relapse transplant toxicities application bone marrow transplantation BMT treatment hematologic malignancies elevated levels tumor necrosis factor alpha TNF-alpha development transplant complications phase I-II trial pentoxifylline PTX xanthine derivative capable down-regulating TNF-alpha production patients hematologic malignancies BMT Thirty consecutive adult patients median age allogeneic autologous BMT Patients dose levels mg/d day day posttransplant PTX significant adverse side effects dose levels actuarial day survival patients confidence interval good risk control group PTX experienced mucositis days hepatic venocclusive disease incidence renal insufficiency days total parenteral nutrition TPN hospital controls day addition incidence graft-versus-host disease GVHD equal II PTX recipients PTX doses excess mg/d severity mucositis TPN requirements hospital discharge patients mg/d PTX study oral administration PTX mg/d reduction morbidity mortality patients undergoing BMT Prospective randomized trials progress preliminary observations